In answer to the perennial question, “why is there no cure for cancer”, Ed Yong from Discover Magazine discusses the complexity of the tumor microenvironment and why this makes finding new therapeutics especially challenging.
In this weeks news:
- Mouse ‘avatars’ could aid pancreatic cancer therapy : Nature News & Comment
Mouse ‘avatars’ could in future allow physicians to find the most effective cocktail of cancer drugs to combat a particular tumour before giving them to a patient, according to researchers at the annual meeting of the Human Genome Organisation (HUGO) in Australia last week.
- Processed meat raises risk for pancreatic cancer? – Health Jockey
A recent report talked of the role played by a protein complex in pancreatic cancer. This study by experts at Karolinska Institutet has disclosed that processed meat could elevate the risk for pancreatic cancer.
- Sulfonylureas and insulin linked to increased risk for pancreatic cancer | HemOncToday
Use of sulfonylureas and insulin was associated with an increased risk for pancreatic cancer, whereas metformin use was associated with a decreased risk for pancreatic cancer in women, according to study results published in The American Journal of Gastroenterology.
To determine the association between antidiabetic drug use, diabetes and the risk for pancreatic cancer, researchers conducted a case-control study of drug prescription, diagnostic, hospitalization and fatality information collected by the British General Practice Research Database (GPRD) between 1995 and 2009.
- INTERNATIONAL CANCER GENOME CONSORTIUM | ICGC launches new project and releases more genomic data on cancer
- Peregrine’s cancer drug data disappoints; shares plunge | Reuters
Peregrine Pharmaceuticals (PPHM.O) said an independent assessment of data from a mid-stage trial showed unexpectedly high progression-free survival rates in lung cancer patients receiving standard chemotherapy, raising doubts about the future of its lung cancer trial.
- Boulder-based Clovis Oncology reports 2011 results – Boulder Daily Camera
- Molecular Way to Control Pancreatic Cancer | www.dailyrx.com
- MIT-Harvard project to fund cancer research teams – Mass High Tech Business News
- InnoCentive and the Sandler-Kenner Foundation Join Forces to Fight Pancreatic Cancer – MarketWatch
- Cell-based pancreatic cancer vaccine increases survival – FierceVaccines
Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.
- Inaugural Article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma
- EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer.
- Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations.
- Metformin and cancer stem cells: old drug, new targets.
- Aberrations and Therapeutics Involving the Developmental Pathway Hedgehog in Pancreatic cancer.
- EZH2 couples pancreatic regeneration to neoplastic progression
- Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.
- Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
- Regulation of pancreatic cancer growth by superoxide.
- Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.
- The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways.
- Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation.
- Down-regulation of yes associated protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.
- Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.
- Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis.
- Effectiveness of Nestin-targeting Therapy in Pancreatic Cancer.
- Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
- Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy.
- Transforming Growth Factor Beta Receptor I Inhibitor Sensitizes Drug-resistant Pancreatic Cancer Cells to Gemcitabine.
- PDGFR? expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker.